Evidence map›Paper›PMID 30390333›Full record

ArticleJournal of cellular biochemistry2019

Optimization of prostate cancer cell detection using multiplex tyramide signal amplification.

Sounak Roy, Haley D Axelrod, Kenneth C Valkenburg, Sarah Amend, Kenneth J Pienta

Open access · hybridAbstract read
In one paragraph

Article in Journal of cellular biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sounak RoyThe Johns Hopkins University, The Krieger School of Arts & Sciences, Baltimore, Maryland.ORCID 0000-0003-1528-1741
Haley D AxelrodThe James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Kenneth C ValkenburgThe James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sarah AmendThe James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Kenneth J PientaThe James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins University · US

Funding

Tumor microvesicle-mediated modulation of the bone microenvironmentP01CA093900 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIENTA, KENNETH J. · 2004 to 2024
$29.6M
Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
The Role of Physical Cues in Collective Cell InvasionU54CA210173 · NCI · JOHNS HOPKINS UNIVERSITY · PI PIENTA, KENNETH J., WIRTZ, DENIS · 2016 to 2020
$9.9M
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer ProgressionU01CA143055 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIENTA, KENNETH J., ROWLEY, DAVID R · 2010 to 2014
$2.7M
Spatiotemporal Regulation of Chk1 in Cell Biology, Cancer Etiology and TherapyR01CA163214 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI ZHANG, YOU-WEI · 2012 to 2016
$1.6M
Targeting SDF1/CXCR4 signaling to mobilize and kill circulating and disseminated prostate tumor cellsF32CA206394 · NCI · JOHNS HOPKINS UNIVERSITY · PI VALKENBURG, KENNETH C · 2016 to 2017
$112k
NCI NIH HHS F32 CA206394NCI NIH HHS P01 CA093900NCI NIH HHS R01 CA163214NCI NIH HHS U01 CA143055NCI NIH HHS U54 CA210173NIGMS NIH HHS T32 GM008752NIH HHS F32CA206394NIH HHS P01CA093900NIH HHS U01CA143055NIH HHS U54CA163214NIH HHS U54CA210173
6 · The paper itself

Abstract

Approximately 29 000 men die of prostate cancer (PCa) each year in the United States, and 90% to 100% of them are due to incurable bone metastasis. It is difficult to determine (1) when PCa disseminates in the natural history of the disease; (2) where cancer cell disseminates before becoming overt metastatic lesions; and (3) which tumors are aggressive and which are indolent. Tumor tissue and liquid (blood and bone marrow) biopsies provide important information to answer these questions, but significant limitations exist for immunostaining strategies that assess protein expression in these tissues. Classic immunohistochemistry (IHC) assays can typically assess expression of one or two proteins per tissue section. We have developed a novel immunofluorescence staining protocol to detect a panel of seven proteins on PCa tissue from primary tumor biopsies and metastatic lesion autopsy tissue, as well as cancer cells from liquid biopsies. We used a tyramide-based system to amplify the true signal and optimized the protocol to reduce background signal, thereby boosting the signal-to-noise ratio. Any protein-specific antibody in this protocol can be exchanged for a different validated antibody. This protocol therefore, represents a highly informative and flexible assay that can be used to provide important information about cancer tissue for the purpose of improving detection, diagnosis, and treatment.

Indexed as

AnimalsAntigens, SurfaceBiotinBone NeoplasmsCell Line, TumorFluorescent Antibody TechniqueFluorescent DyesGlutamate Carboxypeptidase IIHeterograftsHumansIndolesKallikreinsMaleMembrane ProteinsMiceMice, Inbred NODalpha-methylacyl-CoA racemaseAntigens, SurfaceAR protein, humanBiotinbiotinyltyramideDAPIFluorescent DyesFOLH1 protein, humanGlutamate Carboxypeptidase IIIndolesKallikreinsKLK3 protein, humanMembrane ProteinsNucleolinPhosphoproteinsProstate-Specific AntigenprosteinRacemases and EpimerasesReceptors, AndrogenRNA-Binding ProteinsTyraminedetectionimmunofluorescencemetastasisprostate cancertumor microarraytyramide

Identifiers

PMID30390333
PMCPMC6519224
OpenAlexW2899301461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.